It also said that it has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. By the end of February the FDA had received more than 455 reports of adverse events with compounded semaglutide and more than 320 reports of adverse events with compounded tirzepatide
by Rylan Rosario, MA, CBHC Fall 2024 When it comes to managing weight, the focus is often Read Article by Melissa Mitri, MS, RDN Fall 2024 Ultra-processed foods (UPFs) have become a staple in modern diets, Read Article by Rachel Goldman, PhD, FTOS
Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial
[DOI] [PubMed] [Google Scholar] 5.Jarrett SG, Milder JB, Liang LP, Patel M